| Literature DB >> 29526696 |
Yusuke Tarumoto1, Bin Lu1, Tim D D Somerville1, Yu-Han Huang1, Joseph P Milazzo1, Xiaoli S Wu2, Olaf Klingbeil1, Osama El Demerdash1, Junwei Shi3, Christopher R Vakoc4.
Abstract
The lineage-specific transcription factor (TF) MEF2C is often deregulated in leukemia. However, strategies to target this TF have yet to be identified. Here, we used a domain-focused CRISPR screen to reveal an essential role for LKB1 and its Salt-Inducible Kinase effectors (SIK3, in a partially redundant manner with SIK2) to maintain MEF2C function in acute myeloid leukemia (AML). A key phosphorylation substrate of SIK3 in this context is HDAC4, a repressive cofactor of MEF2C. Consequently, targeting of LKB1 or SIK3 diminishes histone acetylation at MEF2C-bound enhancers and deprives leukemia cells of the output of this essential TF. We also found that MEF2C-dependent leukemias are sensitive to on-target chemical inhibition of SIK activity. This study reveals a chemical strategy to block MEF2C function in AML, highlighting how an oncogenic TF can be disabled by targeting of upstream kinases.Entities:
Keywords: HDAC4; LKB1; MEF2C; MLL; SIK2; SIK3; acute myeloid leukemia; kinase; salt-inducible kinase; transcription
Mesh:
Substances:
Year: 2018 PMID: 29526696 PMCID: PMC5856641 DOI: 10.1016/j.molcel.2018.02.011
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 19.328